Guidance for Valeant Pharmaceuticals International (BHC)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2024 | N/A | N/A | $9.30B – 9.55B | $8.97B | = Maintained | Details |
| 2023 | N/A | N/A | $8.35B – 8.55B | $8.34B | = Maintained | Details |
| 2023 | N/A | N/A | $8.45B – 8.65B | $8.35B | = Maintained | Details |
| 2022 | N/A | N/A | $8.40B – 8.60B | $11.22B |  Lowered |
Details |
| 2022 | N/A | N/A | $8.25B – 8.40B | $11.09B | = Maintained | Details |
| 2022 | N/A | N/A | $8.05B – 8.22B | $8.34B | = Maintained | Details |
| 2022 | N/A | N/A | $8.00M – 8.17M | N/A | Lowered |
Details |
| 2021 | N/A | N/A | $8.40B – 8.60B | $8.64B |  Raised |
Details |
| 2021 | N/A | N/A | $8.40B – 8.60B | N/A | = Maintained | Details |
| 2020 | N/A | N/A | $8.65B – 8.85B | $8.78B | = Maintained | Details |
| 2020 | N/A | N/A | $7.80B – 8.00B | $7.89B | = Maintained | Details |
| 2020 | N/A | N/A | $7.80B – 8.00B | $8.05B | = Maintained | Details |
| 2019 | N/A | N/A | $8.30B – 8.50B | $8.49B | Lowered |
Details |
| 2019 | N/A | N/A | $8.35B – 8.55B | $8.47B | Raised |
Details |
| 2019 | N/A | N/A | $8.40B – 8.60B | $8.50B | = Maintained | Details |
| 2018 | N/A | N/A | $8.10B – 8.30B | N/A | = Maintained | Details |
| 2018 | N/A | N/A | $8.15B – 8.35B | $8.24B | = Maintained | Details |
| 2018 | N/A | N/A | $8.15B – 8.35B | $8.32B | = Maintained | Details |
| 2018 | N/A | N/A | $8.15B – 8.35B | N/A | = Maintained | Details |
| 2017 | N/A | N/A | $8.90B – 9.10B | $8.97B | = Maintained | Details |
| 2017 | N/A | N/A | $8.65M – 8.80M | N/A | = Maintained | Details |
| 2017 | $3.60 – $3.75 | N/A | $8.70B – 8.90B | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2016 | $9.50 – $10.50 | $13.24 | $11.00B – 11.20B | $12.41B | = Maintained | Details |
| 2016 | $5.30 – $5.50 | $6.45 | $9.55B – 9.65B | $9.92B | Lowered |
Details |
| 2016 | $6.60 – $7.00 | $8.47 | $9.90B – 10.10B | $10.86B | Lowered |
Details |
| Q1 2016 | $1.30 – $1.55 | $2.63 | $2.30B – 2.40B | $2.82B | = Maintained | Details |
| 2015 | $11.50 – $11.80 | N/A | $10.70B – 11.10B | N/A | Raised |
Details |
| 2015 | $11.67 – $11.87 | N/A | N/A | N/A | Raised |
Details |
| Q4 2015 | $4.00 – $4.20 | N/A | N/A | N/A | Raised |
Details |
| Q3 2015 | $2.60 – $2.70 | N/A | $2.60B – 2.80B | N/A | = Maintained | Details |
| 2013 | $5.55 – $5.85 | N/A | $4.40B – 4.80B | N/A | Raised |
Details |
| 2013 | $6.11 – $6.16 | N/A | N/A | N/A | = Maintained | Details |
| 2012 | $4.45 – $4.70 | N/A | $3.40B – 3.60B | N/A | Raised |
Details |
| 2012 | $4.55 – $4.75 | $4.51 | N/A | N/A | = Maintained | Details |
| 2012 | $4.60 – $4.65 | N/A | N/A | N/A | = Maintained | Details |
| Q4 2012 | $1.30 – $1.35 | N/A | N/A | N/A | = Maintained | Details |
| 2011 | $2.45 – $2.70 | N/A | N/A | N/A | = Maintained | Details |
| 2011 | $2.70 – $3.00 | N/A | N/A | N/A | Raised |
Details |
| 2011 | $2.65 – $2.90 | N/A | N/A | N/A | = Maintained | Details |
